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Background. The methodology commonly used to estimate disease burden, featuring ratings of severity of individual
conditions, has been criticized for ignoring co-morbidity. A methodology that addresses this problem is proposed and
illustrated here with data from the World Health Organization World Mental Health Surveys. Although the analysis
is based on self-reports about one’s own conditions in a community survey, the logic applies equally well to analysis
of hypothetical vignettes describing co-morbid condition proﬁles.
Method. Face-to-face interviews in 13 countries (six developing, nine developed ; n=31 067 ; response rate=69.6%)
assessed 10 classes of chronic physical and nine of mental conditions. A visual analog scale (VAS) was used to assess
overall perceived health. Multiple regression analysis with interactions for co-morbidity was used to estimate associ-
ations of conditions with VAS. Simulation was used to estimate condition-speciﬁc eﬀects.
Results. The best-ﬁtting model included condition main eﬀects and interactions of types by numbers of conditions.
Neurological conditions, insomnia and major depression were rated most severe. Adjustment for co-morbidity re-
duced condition-speciﬁc estimates with substantial between-condition variation (0.24–0.70 ratios of condition-speciﬁc
estimates with and without adjustment for co-morbidity). The societal-level burden rankings were quite diﬀerent
from the individual-level rankings, with the highest societal-level rankings associated with conditions having high
prevalence rather than high individual-level severity.
Conclusions. Plausible estimates of disorder-speciﬁc eﬀects on VAS can be obtained using methods that adjust for
co-morbidity. These adjustments substantially inﬂuence condition-speciﬁc ratings.
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Introduction
It is becoming increasingly clear that no country can
aﬀord to provide universal healthcare coverage for all
illnesses to all citizens. Triage rules are needed to
allocate available healthcare resources to deal with
the inevitable shortfall between resources and need.
Among the several kinds of information used to help
develop these rules, comparative illness burden esti-
mates have been especially valuable as a reference
standard for government health policy planners
(Murray & Lopez, 1996 ; Murray et al. 2001 ; Lopez
& Mathers, 2007). A central component of these
estimates is the condition-speciﬁc severity weight, a
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statistic obtained by having expert raters evaluate the
relative burdens of diﬀerent conditions using the per-
son trade-oﬀ method (Murray & Lopez, 1996 ; Murray
et al. 2001 ; WHO, 2004). An important limitation of
this approach is that the vignettes represent single
conditions rather than more realistic cases where an
individual suﬀers from a number of diﬀerent con-
ditions (Fortin et al. 2007). This is an important limi-
tation because methodological research has shown
that condition-speciﬁc severity weights vary as a func-
tion of the presence of co-morbidity (Moussavi et al.
2007).
Previous attempts to take co-morbidity into con-
sideration in estimating condition-speciﬁc illness
burden have been limited by the fact that simplistic
models were used to estimate eﬀects (Verbrugge et al.
1989 ; Maddigan et al. 2005). The current report pres-
ents the results of an analysis aimed at generating
condition-speciﬁc estimates of disease burden in a
more realistic way. The method is illustrated in an
analysis of data collected in general population sur-
veys on the joint associations of health conditions re-
ported by respondents and overall respondent ratings
of perceived health, although the same logic could be
applied to the analysis of complex vignettes describing
co-morbid condition proﬁles.
Method
The sample
Data come from surveys carried out in 15 countries by
the World Health Organization (WHO) World Mental
Health (WMH) Survey Initiative (Kessler & U¨stu¨n,
2008). Of the countries, six are classiﬁed by the World
Bank as developing (Colombia, Lebanon, Nigeria,
Mexico, People’s Republic of China, Ukraine) and nine
as developed (Belgium, France, Germany, Italy, Israel,
Japan, The Netherlands, Spain, and United States of
America) (Table 1). Country-speciﬁc response rates
ranged from 45.9% (France) to 87.7% (Colombia), with
a weighted (by sample size) average response rate
across surveys of 69.6%. All surveys were based on
probability samples of the adult household popu-
lations in the participating countries or regions within
the countries. Respondents were aged 18+ years other
than in Israel, where the minimum age was 21 years.
The upper end of the age range was unbounded in
all countries other than Colombia, Mexico and the
People’s Republic of China, where the upper bound
was 65 years. More details about WMH sampling and
eligibility are reported elsewhere (Heeringa et al.
2008).
All WMH interviews were conducted face-to-face
by trained lay interviewers. Standardized interviewer
training and quality-control procedures were used
(Pennell et al. 2008). Informed consent was obtained
before beginning interviews. Each interview had two
parts. All respondents completed part I, which con-
tained assessments of core mental disorders. The part
II interview, which assessed physical disorders and
correlates, was administered to 100% of respondents
who met lifetime criteria for any of part I mental dis-
order plus a probability subsample of other part I re-
spondents. A part II weight equal to the inverse of the
respondent’s probability of selection into part II was
used to adjust for diﬀerential selection into part II.
Measures
Chronic physical conditions
Physical conditions were assessed with a chronic
conditions checklist based on the US National Health
Interview Survey list (Schoenborn et al. 2003 ; Center
for Disease Control and Prevention, 2004). Respon-
dents were asked to report whether they ever had a
series of symptom-based conditions (e.g. chronic
headaches) and whether a health professional ever
told them they had a series of silent conditions
(e.g. cancer). Information was obtained whether epi-
sodic conditions were still present in the previous
12 months. Checklists like this yield more accurate
reports than estimates derived from responses to
open-ended questions (Baker et al. 2001 ; Knight et al.
2001). These reports were grouped into ten categories
to maximize comparability with previous studies
(Murray et al. 2001). The categories include arthritis,
cancer, cardiovascular disorders (heart attack, heart
disease, hypertension, stroke), chronic pain conditions
(chronic back or neck pain, other chronic pain con-
ditions), diabetes, frequent or severe headaches or
migraines, chronic insomnia, neurological disorders
(multiple sclerosis, Parkinson’s, epilepsy, seizure dis-
orders), digestive disorders (stomach or intestinal
ulcer, irritable bowel disorder) and respiratory dis-
orders (seasonal allergies, asthma, chronic obstructive
pulmonary disease, emphysema).
Mental disorders
Mental disorders were assessed with the WHO
Composite International Diagnostic Interview, version
3.0 (CIDI), a fully structured lay-administered inter-
view designed to generate diagnoses of common
mental disorders according to the deﬁnitions and
criteria of both the International Classiﬁcation of
Diseases, 10th revision (ICD-10) and Diagnostic and
Statistical Manual of Mental Disorders, 4th edition
(DSM-IV) systems (Kessler & U¨stu¨n, 2004, 2008).
DSM-IV criteria are used here. The nine mental
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disorders include major depressive episode, bipolar
disorder I–II, panic–agoraphobia (panic disorder or
agoraphobia without a history of panic disorder),
speciﬁc phobia, social phobia, generalized anxiety
disorder, post-traumatic stress disorder, alcohol abuse
with or without dependence, and drug abuse with
or without dependence. WMH clinical reappraisal
studies have shown that the diagnoses of these dis-
orders based on the CIDI have generally good
concordance with diagnoses based on blinded
clinician-administered reappraisal interviews (Haro
et al. 2006). As with physical conditions, we focus
on mental conditions present at some time in the
12 months before interview.
Health valuation
Respondents were asked to make a health valuation
after all physical and mental conditions had been as-
sessed. We used a 0–100 visual analog scale (VAS)
where 0 represents ‘ the worst possible health a person can
have ’ and 100 represents ‘perfect health ’ to describe
their own overall physical and mental health during
the previous 30 days taking into consideration all the
physical and mental conditions reviewed in the sur-
vey. The recall period for the VAS (30 days) is diﬀerent
from that for the conditions (12 months) because we
wanted to include eﬀects not only of active conditions
but also of recent conditions that, although not active,
might still have an important eﬀect on health valu-
ations (e.g. a heart attack that occurred several months
before the interview). The decision to anchor the low
end of the scale as deﬁning ‘ the worst possible health ’
rather than ‘death ’ is consistent with the approach
taken in the widely-used EQ-5DTM self-report ques-
tionnaire (http://www.euroqol.org) and was taken in
the WMH surveys based on the ﬁnding in previous
research that some health states are valued lower than
death (Macran & Kind, 2001). While the decision
regarding which of these alternative lower-bound
anchors to use probably had little eﬀect on the esti-
mates of relative disease burden reported here, it is
noteworthy that an explicit valuation of death would
be needed if we wanted to use the data to calculate
years of life lived in less than perfect health.
Analysis methods
A series of multiple regression models was used to
estimate joint predictive associations of conditions
with VAS scores controlling age, sex and country. As
the sample size was too small to allow each of the
524 288 (219) logically possible multivariate condition
proﬁles to be a separate predictor, the models necess-
arily made simplifying assumptions about eﬀects of
co-morbidity. The ﬁrst multivariate model (M1) as-
sumed additivity ; that is, a separate predictor for
each condition without interactions. M2 included a
series of predictors for number of conditions (e.g. one
predictor for having exactly one condition, another
for exactly two, etc) without information about type
of condition. M3 included 19 predictors for type and
number of conditions. The number-of-conditions
dummies in this model represent aggregate patterns
of co-morbidity assumed independent of types. M4
allowed for the eﬀects of type to be a linear function of
number of other conditions. More complex models
allowed for interactions of type with number using
weighted counts based on type coeﬃcients, but these
results are not reported because the models did not ﬁt
the data as well as the simpler models.
The skewed distribution of the VAS scores made
ordinary least-squares (OLS) regression analysis both
biased and ineﬃcient. This problem was addressed in
two ways. First, a two-part modeling approach (Duan
et al. 1984) was used where a part I logistic regression
equation (Hosmer & Lemeshow, 2001) predicted
having a VAS score of 100 v.<100 in the total sample
and a part II linear regression equation predicted
scores in the 0–99 range. Individual-level predicted
scores were estimated by multiplying predicted values
based on the two equations. A problem with this
approach is that non-random variance in prediction
errors can lead to bias even when sophisticated trans-
formation methods are used (Manning, 1998). A
second approach, generalized linear models (GLM),
was used to address that problem by pre-specifying
non-linear associations and non-random error struc-
tures in one-part models. Such models can sometimes
ﬁt highly skewed data better than two-part models
(McCullagh & Nelder, 1989 ; Mullahy, 1998 ; Manning
& Mullahy, 2001). We used a number of diﬀerent two-
part model speciﬁcations and a number of standard
GLM speciﬁcations and then selected the best speciﬁ-
cation using standard empirical model comparison
procedures (Buntin & Zaslavsky, 2004). All models
were estimated separately in developed and develop-
ing countries in an eﬀort to obtain a rough indication
of variation in results by development, but no attempt
was made to estimate country-speciﬁc models.
M4, which allowed the eﬀects of co-morbidity to
vary by type of condition as a linear function of num-
ber of other conditions, was the best-ﬁtting model.
This is a model of intermediate complexity in that it
allows interactions to vary across conditions but not
across particular pairs or higher numbers of disorders.
Although this is unlikely to be the optimal interaction
model, the fact that it provides the best ﬁt across the
range of models considered suggests that it is a use-
ful ﬁrst approximation. But a complication, as in any
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Table 1. Sample characteristics of the WMH Surveys
Country by
income
category Survey Sample characteristicsa Field dates
Age
range,
years
Sample size
Response
ratebPart I Part II
I. Developing
Colombia NSMH Stratiﬁed multistage clustered area probability sample of household residents in all urban
areas of the country (approximately 73% of the total national population)
2003 18–65 4426 2381 87.7
Lebanon LEBANON Stratiﬁed multistage clustered area probability sample of household residents. NR 2002–3 18+ 2857 1031 70
Mexico M-NCS Stratiﬁed multistage clustered area probability sample of household residents in all urban
areas of the country (approximately 75% of the total national population)
2001–2 18–65 5782 2362 76.6
Nigeria NSMHW Stratiﬁed multistage clustered area probability sample of households in 21 of the 36 states in
the country, representing 57% of the national population. The surveys were conducted
in Yoruba, Igbo, Hausa and Eﬁk languages
2002–3 18+ 6752 2143 79.3
People’s Republic
of China
B-WMH Stratiﬁed multistage clustered area probability sample of household residents in the Beijing
and Shanghai metropolitan areas
2002–3 18+ 5201 1628 74.7
S-WMH
Ukraine CMDPSD Stratiﬁed multistage clustered area probability sample of household residents. NR 2002 18+ 4725 1720 78.3
II. Developed
Belgium ESEMeD Stratiﬁed multistage clustered probability sample of individuals residing in households from
the national register of Belgium residents. NR
2001–2 18+ 2419 1043 50.6
France ESEMeD Stratiﬁed multistage clustered sample of working telephone numbers merged with a reverse
directory (for listed numbers). Initial recruitment was by telephone, with supplemental
in-person recruitment in households with listed numbers. NR
2001–2 18+ 2894 1436 45.9
Germany ESEMeD Stratiﬁed multistage clustered probability sample of individuals from community resident
registries. NR
2002–3 18+ 3555 1323 57.8
Israel NHS Stratiﬁed multistage clustered area probability sample of individuals from a national resident
register. NR
2002–4 21+ 4859 4859 72.6
Italy ESEMeD Stratiﬁed multistage clustered probability sample of individuals from municipality resident
registries. NR
2001–2 18+ 4712 1779 71.3
Japan WMHJ
2002–2004
Unclustered two-stage probability sample of individuals residing in households in seven
metropolitan areas (Fukiage, Higashi-ichiki, Ichiki, Kushikino, Nagasaki, Okayama, Tamano)
2002–4 20+ 2437 887 58.4
The Netherlands ESEMeD Stratiﬁed multistage clustered probability sample of individuals residing in households that are
listed in municipal postal registries. NR
2002–3 18+ 2372 1094 56.4
Spain ESEMeD Stratiﬁed multistage clustered area probability sample of household residents. NR 2001–2 18+ 5473 2121 78.6
United States NCS-R Stratiﬁed multistage clustered area probability sample of household residents. NR 2002–3 18+ 9282 5692 70.9
WMH, World Mental Health ; NSMH, The Colombian National Study of Mental Health ; LEBANON, Lebanese Evaluation of the Burden of Ailments and Needs of the Nation ; NR,
nationally representative ; M-NCS, TheMexico National Comorbidity Survey ; NSMHW, The Nigerian Survey of Mental Health andWellbeing ; B-WMH, The BeijingWorldMental Health
Survey ; S-WMH, The Shanghai World Mental Health Survey ; CMDPSD, Comorbid Mental Disorders during Periods of Social Disruption ; ESEMeD, The European Study of the
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interaction model, is that the coeﬃcients have no
intuitive interpretation. We addressed this problem by
using individual-level simulation to transform coef-
ﬁcients to a scale of average decrement in VAS scores
associated with each condition. This was done by
generating two estimates of predicted VAS scores for
each respondent from each simulation. The ﬁrst esti-
mate was based on the model parameters in M4, while
the second estimate was based on a revision of this
model that assumed none of the respondents had one
particular focal condition. The ﬁrst estimate was then
subtracted from the second and the sum across re-
spondents was divided by the number of respondents
with the focal condition to estimate the average indi-
vidual-level decrease in VAS scores associated with
that condition taking co-morbidity into consideration.
This estimate was then projected to the societal level
(i.e. the eﬀect on the mean VAS score) by multiplying
it by condition prevalence.
It is noteworthy that the simulation approach, by
virtue of the fact that it works with mean VAS scores,
treats the VAS as an interval scale. This assumption
has been called into question in some previous studies
(Krabbe et al. 2006 ; Parkin & Devlin, 2006) and non-
linear monotonic transformations have been proposed
to approximate interval scale properties (Krabbe,
2008). However, strong linear associations have been
found between health state values based on VAS
scores and ordinal (Craig et al. 2009) or partially metric
(Krabbe et al. 2007) scaling methods. As a result, and
given that we explored a number of diﬀerent non-
linear transformations of the VAS in the GLM models,
we treated the VAS as an interval scale in the current
analysis.
Because the WMH sample design featured weight-
ing and clustering, all multiple regression analyses
used the Taylor series linearization method (Wolter,
1985) implemented in the SUDAAN software system
(2002 ; Research Triangle Institute, USA). Standard
errors of simulation estimates were obtained using
the method of Jackknife repeated replications (Wolter,
1985) implemented with a SAS macro (SAS/STAT1
software, version 9.1 for Unix, SAS Institute, Inc.,
USA). Statistical signiﬁcance was consistently evalu-
ated using two-sided 0.05 level tests.
Results
Condition prevalence estimates
More than half of all respondents reported having one
or more conditions in the 12 months before interview
(Table 2). Of those with any conditions, 54.6% had
more than one and 51% of those with more than
one had more than two conditions. The majority ofE
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conditions were reported to be more prevalent in
developed than developing countries.
Distribution of VAS scores
VAS scores are distributed quite similarly in devel-
oping and developed countries. Fewer than 10%
of respondents in either set of countries have scores
below 50, while 20.8% have scores of 100 and an
additional 7.4% have scores in the range 91–100. The
median among respondents with scores less than 100
is 80 [interquartile range (IQR)=70–90] in both
developing and developed countries.
Selecting a functional form and error structure for
the models
We estimated seven one-part GLM models and seven
two-part models. We evaluated comparative model
ﬁt by plotting associations between predicted mean
VAS scores and observed mean scores for each decile
of predicted VAS scores and using a number of other
model-ﬁtting tests that have been proposed in the
econometrics literature (Buntin & Zaslavsky, 2004)
(detailed results are available on request). The GLM
model with a square root functional form and inde-
pendent error structure and the one-part OLS model
were found to be the best-ﬁtting models in terms of all
the tests we considered. Based on this result and the
simpler interpretation of the OLS model than the GLM
model, we chose the OLS model.
The individual-level predictive associations of
conditions with VAS scores
The coeﬃcients in M1 are signiﬁcant as a set and show
each condition to have a negative predictive associ-
ation with VAS scores (Table 3). (Only a single illustra-
tive ﬁt statistic is shown in Table 3. More detailed
results for each model are available on request.) The
coeﬃcients in M2 are also signiﬁcant as a set and
show that VAS scores decrease monotonically with
Table 2. Twelve-month prevalence estimates of chronic physical conditions and mental conditions separately in WMH Surveys in
developing and developed countries
Developing countries
(n=10 836)
Developed countries
(n=20 231)
All countries
(n=31 067)
I. Chronic physical conditions 47.1 (0.8) 56.1 (0.6) 52.9 (0.5)
Arthritis 11.5 (0.4) 15.6 (0.4) 14.2 (0.3)
Cancer 0.5 (0.1) 3.2 (0.2) 2.2 (0.1)
Cardiovascular disorders 14.3 (0.5) 18.9 (0.3) 17.3 (0.3)
Chronic pain conditions 22.5 (0.6) 22.7 (0.4) 22.6 (0.3)
Diabetes 2.7 (0.2) 5.3 (0.2) 4.3 (0.1)
Digestive disorders 5.0 (0.3) 2.7 (0.1) 3.5 (0.1)
Headaches or migraines 14.5 (0.5) 11.4 (0.3) 12.5 (0.3)
Insomnia 3.2 (0.2) 5.1 (0.2) 4.4 (0.2)
Neurological disorders 1.0 (0.1) 1.1 (0.1) 1.0 (0.1)
Respiratory disorders 12.0 (0.5) 19.8 (0.5) 17.1 (0.4)
II. Mental conditions 12.7 (0.4) 15.1 (0.4) 14.2 (0.3)
Alcohol abuse 2.4 (0.2) 1.5 (0.1) 1.8 (0.1)
Bipolar disordera 1.0 (0.1) 2.1 (0.2) 1.6 (0.1)
Drug abuseb 0.3 (0.1) 0.8 (0.1) 0.6 (0.1)
Generalized anxiety disorder 0.5 (0.1) 1.6 (0.1) 1.2 (0.1)
Major depressive episode 4.9 (0.2) 6.4 (0.2) 5.8 (0.1)
Panic disorder 1.2 (0.1) 1.8 (0.1) 1.6 (0.1)
Post-traumatic stress disorder 0.8 (0.1) 1.7 (0.1) 1.4 (0.1)
Social phobiac 1.5 (0.1) 3.5 (0.2) 2.7 (0.1)
Speciﬁc phobiad 5.4 (0.3) 6.6 (0.3) 6.2 (0.2)
III. Any condition 52.0 (0.8) 60.3 (0.6) 57.3 (0.5)
WMH, World Mental Health.
Values are given as percentage (standard error).
a Bipolar disorder was not assessed in Belgium, France, Germany, Israel, Italy, The Netherlands, Nigeria, Spain and Ukraine.
b Drug abuse was not assessed in Belgium, France, Germany, Italy, The Netherlands and Spain.
c Social phobia was not assessed in Israel.
d Speciﬁc phobia was not assessed in Israel and Ukraine.
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number of conditions. The M3 results show that the
individual conditions continue to have generally
negative coeﬃcients when controlling for number of
conditions and that the coeﬃcients vary signiﬁcantly
across conditions. The coeﬃcients associated with
number of conditions in M3 are signiﬁcantly negative.
This indicates sub-additive interactions : that the joint
adverse associations of co-morbid condition clusters
with VAS scores are less than the sum of the associ-
ations of the individual pure conditions in the clusters
taken one at a time. M4 shows that these non-additive
associations vary signiﬁcantly across conditions.
Simulated individual-level estimates
Transformation of theM4 coeﬃcients using simulation
shows that the condition-speciﬁc individual-level esti-
mates are consistently negative (Table 4). Coeﬃcients
for only two conditions (digestive disorders and speci-
ﬁc phobia) diﬀer signiﬁcantly between developing
and developed countries (both higher in developed).
Magnitude of estimates is also quite similar in devel-
oping versus developed countries, with median values
on the 0–100 VAS of 5.4 (IQR=3.2–5.8) in develop-
ing and 4.9 (IQR=3.1–7.1) in developed countries.
Diﬀerences in coeﬃcients across conditions are
statistically signiﬁcant in the total sample and
fairly consistent in developing versus developed coun-
tries. The Spearman rank-order correlation among
condition estimates between developed and develop-
ing countries is 0.54. The most notable exception is
drug abuse, ranked 1st in developing countries and
14th in developed countries.
Coeﬃcients based on the bivariate model (i.e. con-
sidering only one condition at a time in predicting
VAS) are consistently higher than those in the multi-
variate model, with the condition-speciﬁc ratio of the
latter to former in the range 0.24–0.70 and a median
ratio of 0.42 (IQR=0.31–0.51) (Table 5) Very similar
results are found in developing [0.53 (IQR=0.35–0.62)]
and developed [0.41 (IQR=0.27–0.51)] countries. The
inﬂuence of co-morbidity can be seen in the fact
that the correlation across conditions between mean
number of co-morbid conditions (last column, Table 5)
and the ratio of the coeﬃcient based on the bivariate
model to the coeﬃcient based on the multivariate
model (penultimate column, Table 5) is a statistically
signiﬁcantx0.46.
Simulated societal-level predictive associations
of conditions with mean VAS scores
Societal-level associations are a joint function of
prevalence and severity. We derived these estimates
by multiplying individual-level estimates by the
condition prevalence estimates to arrive at estimated
associations of conditions with changes in mean VAS
scores in the population (Table 6). Of the coeﬃcients,
Table 3. Model comparisons for the multivariate associations of conditions on VAS scores
separately in WMH Surveys in developing and developed countries
Model
AICa
Developing
countries
Developed
countries
All
countries
M1.Types of disordersb 95788.4 176722.1 272549.3
M2. Number of disordersc 95874.6 177062.4 273024.7
M3. Types and number of disordersd 95757.2 176703.4 272527.5
M4. M3+interactions between types
and number of disorderse
95751.10f 176628.86f 272468.16f
VAS, Visual analog scale ; WMH,World Mental Health ; AIC, Akaike’s Information
Criterion.
a Only one illustrative test statistic, AIC, is reported in this table, but model
comparison was based on a number of diﬀerent tests. For a description, see the text.
b A separate dummy variable predictor for each of the 19 conditions.
c A separate dummy variable predictor for having exactly one of the 19 disorders,
exactly two of the 19 disorders, etc.
d The predictors in M1 and M2 with the exception that the dummy predictor for
having exactly one disorder is omitted.
e The predictors in M3 plus interactions between each of the dummy predictors for
type of disorders and a continuous variable for number of disorders.
f Best-ﬁtting model.
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eight diﬀer signiﬁcantly between developing and de-
veloped countries, all but one higher in developed
countries. The median value of the coeﬃcients is quite
similar in developing [0.09 (IQR=0.03–0.23)] and
developed [0.14 (IQR=0.07–0.40)] countries.
While most societal-level coeﬃcients do not diﬀer
signiﬁcantly by development, 74.8% of the 171 (19r
18/2) diﬀerences between pairs of the 19 coeﬃcients
are statistically signiﬁcant at the 0.05 level in the total
sample. The Spearman rank-order correlation among
these conditions between sets of countries is 0.80. The
top ﬁve conditions are the same in developing and
developed countries, although the rankings diﬀer
somewhat. These top conditions are dominated by
high-prevalence conditions with intermediate magni-
tudes of individual-level eﬀects (6th–13th ranks), with
only chronic pain conditions major depression being
in the top ﬁve in terms of magnitude of individual-
level eﬀects.
Discussion
A number of limitations must be considered in inter-
preting these results. First, only a restricted set of
common conditions was included in the analysis and
some were pooled to form larger disorder groups. A
number of burdensome conditions, such as dementia
and psychosis, were not included. Expansion and
disaggregation is clearly needed in future research.
Second, diagnoses of chronic physical conditions were
based on self-reports that could have been biased.
Such bias might account for the generally higher
prevalence estimates of these conditions in developed
than developing countries. Third, we focused on
12-month prevalence of conditions but 30-day health
valuations, as these were the time-frames included in
the WMH surveys. This diﬀerence in recall periods
would be expected to lead to an underestimate of the
severity of the active phases of episodic conditions
Table 4. Simulated individual-level condition-speciﬁc severity estimates based on the best-ﬁtting regression model separately in WMH
Surveys in developing and developed countries
Developing countries Developed countries All countries
Estimate (S.E.) Rank Estimate (S.E.) Rank Estimate (S.E.) Rank
I. Chronic physical conditions
Arthritis x4.6 (0.7)* 13 x4.8 (0.5)* 11 x4.9 (0.4)* 10
Cancer x3.2 (4.1) 14 x0.6 (0.9) 19 x0.8 (0.9) 19
Cardiovascular disorders x5.3 (0.7)* 8 x5.0 (0.5)* 9 x4.9 (0.4)* 9
Chronic pain conditions x5.8 (0.7)* 6 x7.1 (0.4)* 6 x6.8 (0.4)* 4
Diabetes x6.1 (1.7)* 5 x6.0 (0.9)* 7 x6.1 (0.8)* 6
Digestive disorders x0.5 (0.9) 19 x7.2 (1.2)* 5 x4.1 (0.8)*# 14
Headaches or migraines x5.1 (0.7)* 9 x4.1 (0.5)* 13 x4.5 (0.4)* 13
Insomnia x7.2 (1.5)* 4 x7.9 (0.7)* 3 x7.9 (0.7)* 2
Neurological disorders x9.4 (2.3)* 2 x13.1 (1.6)* 1 x12.0 (1.4)* 1
Respiratory disorders x1.6 (0.7)* 16 x1.1 (0.4)* 18 x1.4 (0.4)* 18
II. Mental conditions
Alcohol abuse x4.6 (2.1)* 12 x2.1 (0.9)* 17 x3.2 (1.1)* 15
Bipolar disorder x4.9 (2.6) 11 x5.1 (1.8)* 8 x5.3 (1.5)* 7
Drug abuse x11.7 (4.3)* 1 x3.1 (1.7) 14 x5.2 (1.7)* 8
Generalized anxiety disorder x1.1 (2.3) 17 x4.9 (1.3)* 10 x4.5 (1.1)* 12
Major depressive episode x7.3 (0.9)* 3 x7.9 (0.7)* 2 x7.6 (0.5)* 3
Panic disorder x5.4 (2.0)* 7 x7.4 (1.2)* 4 x6.7 (1.0)* 5
Post-traumatic stress disorder x5.0 (2.2)* 10 x4.3 (1.0)* 12 x4.7 (0.9)* 11
Social phobia x2.2 (1.3) 15 x2.6 (1.0)* 16 x2.6 (0.9)* 16
Speciﬁc phobia x0.6 (0.9) 18 x3.0 (0.8)* 15 x2.3 (0.6)*# 17
III. Any condition
Physical disorders x9.3 (0.5)* x8.2 (0.3)* x8.6 (0.3)*
Mental disorders x6.1 (0.5)* x8.2 (0.4)* x7.4 (0.3)*#
Any disorder x10.3 (0.5)* x9.9 (0.3)* x10.1 (0.3)*
WMH, World Mental Health ; S.E., standard error.
* p<0.05(two-sided test).
# Signiﬁcant diﬀerence between developing and developed countries (p<0.05 ; two-sided test).
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(e.g. migraine), although it should yield an accurate
estimate of the average severity of conditions in a
typical month (30 days) of the year (12 months). A re-
lated limitation is that even a 12-month time-frame is
relatively short compared with the time-frames used
in some other health valuation studies (e.g. 10 years or
lifetime).
Another limitation is that the highly skewed dis-
tribution of VAS scores and non-additive eﬀects of
co-morbid conditions might have led to instability of
results. Even though we explored use of GLM rather
than OLS and examined a number of diﬀerent model
speciﬁcations to capture eﬀects of co-morbidity, it
is possible that future research will discover better
speciﬁcations either of functional form or of joint
associations of co-morbid conditions with health
valuations. In particular, the use of data mining tech-
niques such as regression tree analysis (Breiman et al.
1984 ; Friedman, 1991 ; Breiman, 2001, 2009) might
provide useful insights into better speciﬁcation of
interaction eﬀects. A related limitation is that we
assumed that the VAS is an interval scale. As noted
above in the section on Analysis methods, this
assumption has been called into question in some
previous studies (Krabbe et al. 2006; Parkin & Devlin,
2006). Non-linear monotonic transformations have
been proposed to approximate interval scale proper-
ties (Krabbe, 2008 ; Craig et al. 2009). It would be very
useful in future methodological research to explore
the extent to which these diﬀerent methods inﬂuence
results.
Another limitation is that our estimates were based
only on the overall adult population in developed and
developing countries. The ratings of conditions might
be quite diﬀerent in diﬀerent population segments
(e.g. elderly, women, poor) or in diﬀerent countries.
Future research is needed to investigate these speciﬁ-
cations. The use of anchoring vignettes has been
shown to help address this problem (Salomon et al.
2004). In addition, a number of statistical methods
exist to improve the accuracy of comparisons across
subsamples and populations that could proﬁtably be
used in future applications (Tandon et al. 2002).
Another limitation is that our results are based on
VAS scores assigned by respondents to their own
health states rather than to health states based on
Table 5. Individual-level condition-speciﬁc estimates based on bivariate and the best-ﬁtting multivariate model in the total sample
Bivariatea Multivariate
Multivariate/
bivariateb
estimate
Mean
co-morbidityc
I. Chronic physical conditions
Arthritis x9.5 (0.5) x4.9 (0.4) 0.51 2.0
Cancer x2.6 (1.1) x0.8 (0.9) 0.31 2.1
Cardiovascular disorders x8.4 (0.4) x4.9 (0.4) 0.59 1.8
Chronic pain conditions x10.9 (0.4) x6.8 (0.4) 0.63 1.8
Diabetes x8.8 (1.0) x6.1 (0.8) 0.70 2.0
Digestive disorders x9.9 (0.9) x4.1 (0.8) 0.41 2.3
Headaches or migraines x9.9 (0.4) x4.5 (0.4) 0.45 2.0
Insomnia x16.0 (0.7) x7.9 (0.7) 0.50 2.9
Neurological disorders x17.8 (1.7) x12.0 (1.4) 0.67 2.6
Respiratory disorders x4.3 (0.4) x1.4 (0.4) 0.31 1.6
II. Mental conditions
Alcohol abuse x7.3 (1.1) x3.2 (1.1) 0.44 1.8
Bipolar disorder x17.8 (1.4) x5.3 (1.5) 0.30 3.9
Drug abuse x12.4 (1.8) x5.2 (1.7) 0.42 2.6
Generalized anxiety disorder x13.4 (1.1) x4.5 (1.1) 0.34 3.0
Major depressive episode x14.8 (0.5) x7.6 (0.5) 0.52 2.5
Panic disorder x16.6 (1.0) x6.7 (1.0) 0.40 3.4
Post-traumatic stress disorder x15.3 (1.1) x4.7 (0.9) 0.31 3.5
Social phobia x11.2 (0.8) x2.6 (0.9) 0.24 2.9
Speciﬁc phobia x8.1 (0.6) x2.3 (0.6) 0.29 2.2
Values are given as estimate (standard error).
a Nineteen models with one condition at a time adjusted by demographic controls.
b The ratio of the estimate based on the best-ﬁtting model to the estimate based on the bivariate model.
cMean co-morbidity is the mean number of other conditions reported by respondents with the condition in the row.
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hypothetical vignettes. While there is general agree-
ment that perceptions of people in the general popu-
lation should be taken into consideration in making
health valuations (Gudex et al. 1996), concerns have
been raised that bias exists in the perceptual ratings of
community respondents based on their own illness
experiences (Stiggelbout & de Vogel-Voogt, 2008)
and their familiarity with the experiences of people
close to them (Krabbe et al. 2006), resulting in a
general preference for health valuations made by
experts (Marquie et al. 2003). Furthermore, bias in
self-reports in the WMH data might have been
greater for mental than physical conditions because
so many questions were asked in the survey about
mental conditions and the VAS was administered only
at the end of the survey. It would be useful to inves-
tigate this potential bias in future applications by
randomizing the order of presentation of the VAS
question in the survey. Methods have been developed
to integrate VAS responses with responses based on
other valuation methods (e.g. time trade-oﬀ, will-
ingness to pay) that might also proﬁtably be used in
future studies to evaluate these biases (Salomon &
Murray, 2004).
A less obvious limitation, ﬁnally, is that the simu-
lation method evaluated marginal eﬀects of individual
conditions. This method can be faulted because it im-
plicitly assumes that the presence versus absence of a
single condition can be changed while holding con-
stant all other conditions. This assumption would
be plausible if all co-morbid conditions were either
causes or risk markers (Kraemer et al. 1997) of focal
conditions. However, in cases where the co-morbid
condition is a consequence of the focal condition or
where two or more conditions are reciprocally related,
the simulation method used here will underestimate
the eﬀect of the focal condition (assuming that
co-morbidity is positive) by controlling for one or
Table 6. Societal-level condition-speciﬁc estimates of eﬀects on mean visual analog scale scores based on the best-ﬁtting multivariate
model for developed and developing countries
Developing countries Developed countries All countries
Estimate (S.E.) Rank Estimate (S.E.) Rank Estimate (S.E.) Rank
I. Chronic physical conditions
Arthritis x0.5 (0.1)* 4 x0.8 (0.1)* 3 x0.7 (0.1)* 3
Cancer x0.0 (0.0) 18 x0.0 (0.0) 19 x0.0 (0.0) 19
Cardiovascular disorders x0.8 (0.1)* 2 x0.9 (0.1)* 2 x0.8 (0.1)* 2
Chronic pain conditions x1.3 (0.2)* 1 x1.6 (0.1)* 1 x1.6 (0.1)* 1
Diabetes x0.2 (0.0)* 8 x0.3 (0.0)* 7 x0.3 (0.0)*# 7
Digestive disorders x0.0 (0.0) 15 x0.2 (0.0)* 9 x0.1 (0.0)*# 9
Headaches or migraines x0.7 (0.1)* 3 x0.5 (0.1)* 5 x0.6 (0.0)*# 4
Insomnia x0.2 (0.0)* 6 x0.4 (0.0)* 6 x0.4 (0.0)*# 6
Neurological disorders x0.1 (0.0)* 10 x0.1 (0.0)* 11 x0.1 (0.0)* 10
Respiratory disorders x0.2 (0.1)* 7 x0.2 (0.1)* 8 x0.2 (0.1)* 8
II. Mental conditions
Alcohol abuse x0.1 (0.0)* 9 x0.0 (0.0)* 17 x0.1 (0.0)* 15
Bipolar disorder x0.0 (0.0) 16 x0.0 (0.0)* 16 x0.0 (0.0)* 17
Drug abuse x0.0 (0.0) 13 x0.0 (0.0)* 18 x0.0 (0.0)* 18
Generalized anxiety disorder x0.0 (0.0) 19 x0.1 (0.0)* 13 x0.0 (0.0)*# 16
Major depressive episode x0.4 (0.0)* 5 x0.5 (0.0)* 4 x0.4 (0.0)*# 5
Panic disorder x0.1 (0.0)* 11 x0.1 (0.0)* 12 x0.1 (0.0)*# 12
Post-traumatic stress disorder x0.0 (0.0) 12 x0.1 (0.0)* 14 x0.1* (0.0)* 13
Social phobia x0.0 (0.0) 14 x0.1 (0.0)* 15 x0.1 (0.0)* 14
Speciﬁc phobia x0.0 (0.0) 17 x0.2 (0.0)* 10 x0.1 (0.0)*# 11
III. Any condition
Physical x4.4 (0.2)* x4.6 (0.2)* x4.6 (0.2)*
Mental x0.8 (0.1)* x1.2 (0.1)* x1.1 (0.0)*#
Any x5.4 (0.3)* x5.9 (0.2)* x5.8 (0.2)*
S.E., Standard error.
* p<0.05(two-sided test).
# Signiﬁcant diﬀerence between developing and developed countries (p<0.05 ; two-sided test).
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more of the intervening pathways through which that
condition inﬂuences VAS scores.
This underestimation could be removed by deleting
controls for all conditions that are thought to mediate
the total eﬀect of the focal condition. However, in the
case where these co-morbid conditions are recipro-
cally related to the focal condition, exclusion of the
co-morbid conditions from the prediction equation
will lead to overestimation of the eﬀect of the focal
condition. The only plausible way to address that
issue is to develop a methodology of partial control :
that is, to control for the subset of co-morbid con-
ditions that has causal eﬀects on the focal conditions
but not for the subset that occurs as a consequence
of the focal condition. An innovative methodology
known as g-estimation has been developed to do this
(Young et al. 2010), but this method requires access
to large-scale longitudinal epidemiological data that
monitor onset and course of co-morbid conditions
over time. As a result of this data requirement, use of
g-estimation has been minimal (Taubman et al. 2009)
and has never to our knowledge been used to study
health valuation. This method is nonetheless very
promising and deserves to be explored in future
studies aimed at sorting out the eﬀects of co-morbidity
on health valuation.
Within the context of these limitations, our results
show clearly that sensible estimates can be obtained
of condition-speciﬁc eﬀects on VAS while taking
co-morbidity into consideration. As noted in the Intro-
duction, a similar approach could be used to study
informant ratings by using a series of hypothetical
vignettes of people with co-morbid conditions rather
than pure conditions. We ﬁnd that the consideration
of co-morbidity makes a substantial diﬀerence to
ratings. In particular, condition-speciﬁc ratings are
lower when co-morbidity is taken into consideration
due to a general pattern of sub-additive interactions
among co-morbid conditions in predicting VAS
scores. This sub-additive pattern is consistent with
the ﬁndings of the one other previous study we know
that carried out a similar type of analysis (Verbrugge
et al. 1989). Furthermore, we found substantial
between-condition variation in the extent to which
adjustment for co-morbidity inﬂuences estimates.
Although the substantive ﬁndings regarding eﬀects
of individual conditions on VAS should be interpreted
with caution given the limitations enumerated above,
it is noteworthy that neurological conditions, insomnia
and major depression were estimated to be the most
severe conditions at the individual level. The neuro-
logical conditions we considered included epilepsy
and seizure disorders, Parkinson’s disease and mul-
tiple sclerosis, all of which have been shown to have
high disability in previous studies (Singer et al. 1999 ;
Jacoby & Baker, 2008). The high ranking of insomnia
is surprising because previous studies, although docu-
menting a high societal-level burden of insomnia,
have generally found this to be due to high preva-
lence in conjunction with moderate individual-level
burden rather than to high individual-level burden
(Roth et al. 2006). The high individual-level severity
of insomnia in our study probably lies in the fact
that we required a greater sleep disruption (at least 2 h
of either delay in sleep onset or disruption in sleep
maintenance per night most nights of the week for
at least 1 month in the previous year) than previous
studies of insomnia (Ohayon, 2002). The high indi-
vidual-level estimate we found for depression, ﬁnally,
is consistent with much previous research (Donohue
& Pincus, 2007 ; Wang et al. 2008 ; Gabilondo et al.
2010).
The rank-ordering of the individual-level VAS esti-
mates was found to be quite similar in developing
and developed countries. However, several exceptions
were found. These should be investigated in future
studies. Digestive conditions (stomach/intestine ulcer
and irritable bowel disorder) were rated considerably
more severe in developed than developing countries,
possibly reﬂecting a diﬀerent mix of cases that might
explain the diﬀerences in estimated severity. The
individual-level estimated severity of drug abuse, in
comparison, was substantially higher in developing
than developed countries. Diﬀerential willingness to
admit drug problems might have been involved in
this result, as reported prevalence of drug abuse was
much lower in developing than developed countries,
possibly indicating that the cases we learned of in
developing countries were more severe than those in
developed countries (Schmidt & Room, 1999).
Comparison of our individual-level condition
severity estimates with estimates in an earlier WMH
analysis of condition-speciﬁc role impairment (Ormel
et al. 2008) ﬁnds that the conditions rated most severe
in that earlier study were generally also rated among
the most severe in the current investigation. However,
a number of diﬀerences in relative ratings exist that
could be attributed either to diﬀerences in the outcome
(i.e. a global VAS score versus a measure of condition-
speciﬁc role impairment) or to our previous analysis
not adjusting for co-morbidity.
Our results regarding societal-level associations
are less innovative because, consistent with previous
studies, we merely multiplied the prevalence esti-
mates of the conditions with the individual-level esti-
mates of condition severity to arrive at societal-level
estimates of burden. As in previous studies that com-
pared individual-level and societal-level estimates
(Whiteford, 2000; Andlin-Sobocki et al. 2005 ; Saarni
et al. 2007), the rank-ordering of conditions diﬀers
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considerably between the two, with societal-level
estimates inﬂuenced importantly by variation in
prevalence and the conditions estimated to be most
burdensome at the societal level dominated by high-
prevalence conditions.
While our results argue clearly for the importance
of considering co-morbidity when estimating disease
burden, the best way to do this is not obvious. The
approach we took here has the advantage of con-
sidering co-morbidities in their true distribution in the
population rather than requiring hypothetical scen-
arios to be generated that might or might not ad-
equately characterize the actual distribution of
complex co-morbidities in the population. However,
methods also exist to allow the eﬀects of individual
conditions to be estimated using expert ratings of hy-
pothetical patient scenarios that include information
about complex proﬁles of co-morbidity (Jasso, 2006 ;
Saarni et al. 2007). Indeed, the actual distributions
of co-morbidity found in community surveys like
the WMH surveys could be used to generate these
vignettes so as to guarantee that they represent the
distribution and range of patterns in the population.
As many health policy researchers favor condition
severity ratings made by experts rather than the
ratings made by respondents in community surveys
for a variety of other reasons (Insinga & Fryback, 2003 ;
Marquie et al. 2003; Ormel et al. 2008; Schnadig et al.
2008), it might be that the best approach would be to
build information about co-morbidity into conven-
tional expert rating scenarios. However, valuations of
the sort presented here based on community samples
also would seem to have value in representing the
perceptions of actual people with real conditions in
the population. It remains a challenge for the ﬁeld to
develop a way of integrating data of these diﬀerent
sorts.
Acknowledgements
The analysis for this paper was carried out in con-
junction with the WHO WMH Survey Initiative.
We thank the WMH staﬀ for assistance with instru-
mentation, ﬁeldwork and data analysis. These ac-
tivities were supported by the United States National
Institute of Mental Health (R01MH070884), the
Mental Health Burden Study (contract number
HHSN271200700030C), the John D. and Catherine
T. MacArthur Foundation, the Pﬁzer Foundation,
the US Public Health Service (R13-MH066849, R01-
MH069864 and R01 DA016558), the Fogarty Inter-
national Center (FIRCA R03-TW006481), the Pan
American Health Organization, the Eli Lilly &
Company Foundation, Ortho-McNeil Pharmaceutical,
Inc., GlaxoSmithKline, Bristol-Myers Squibb and
Shire. A complete list of WMH publications can be
found at http://www.hcp.med.harvard.edu/wmh/.
The Chinese WMH Survey Initiative is supported
by the Pﬁzer Foundation. The Colombian National
Study of Mental Health (NSMH) is supported by the
Ministry of Social Protection. The European Study
of the Epidemiology of Mental Disorders (ESEMeD)
project is funded by the European Commission
(contracts QLG5-1999-01042 ; SANCO 2004123), the
Piedmont Region (Italy), Fondo de Investigacio´n
Sanitaria, Instituto de Salud Carlos III, Spain (FIS 00/
0028), Ministerio de Ciencia y Tecnologı´a, Spain
(SAF 2000-158-CE), Departament de Salut, Generalitat
de Catalunya, Spain, Instituto de Salud Carlos III
(CIBER CB06/02/0046, RETICS RD06/0011 REM-
TAP), and other local agencies and by an unrestricted
educational grant from GlaxoSmithKline. The Israel
National Health Survey is funded by the Ministry of
Health with support from the Israel National Insti-
tute for Health Policy and Health Services Research
and the National Insurance Institute of Israel. The
WMH Japan (WMHJ) Survey is supported by the
Grant for Research on Psychiatric and Neurological
Diseases and Mental Health (H13-SHOGAI-023, H14-
TOKUBETSU-026, H16-KOKORO-013) from the Japan
Ministry of Health, Labor and Welfare. The Lebanese
National Mental Health Survey (Lebanese Evaluation
of the Burden of Ailments and Needs of the Nation;
LEBANON) is supported by the Lebanese Ministry
of Public Health, the WHO (Lebanon), Fogarty Inter-
national, Act for Lebanon, anonymous private do-
nations to the Institute for Development, Research,
Advocacy and Applied Care (IDRAAC), Lebanon, and
unrestricted grants from Janssen Cilag, Eli Lilly,
GlaxoSmithKline, Roche and Novartis. The Mexican
National Co-morbidity Survey (MNCS) is supported
by The National Institute of Psychiatry Ramon de la
Fuente (INPRFMDIES 4280) and by the National
Council on Science and Technology (CONACyT-
G30544-H), with supplemental support from the Pan-
American Health Organization (PAHO). The Nigerian
Survey of Mental Health and Wellbeing (NSMHW) is
supported by the WHO (Geneva), the WHO (Nigeria)
and the FederalMinistry ofHealth, Abuja, Nigeria. The
Ukraine Comorbid Mental Disorders during Periods
of Social Disruption (CMDPSD) study is funded by
the US National Institute of Mental Health (RO1-
MH61905). The US National Co-morbidity Survey
Replication (NCS-R) is supported by the National
Institute of Mental Health (NIMH; U01-MH60220)
with supplemental support from the National Institute
of Drug Abuse (NIDA), the Substance Abuse and
Mental Health Services Administration (SAMHSA),
the Robert Wood Johnson Foundation (RWJF; grant
044708) and the John W. Alden Trust.
884 J. Alonso et al.
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0033291710001212
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 11 Jul 2017 at 10:11:14, subject to the Cambridge Core terms of use, available at
Declaration of Interest
R.C.K. has been a consultant for GlaxoSmithKline Inc.,
Kaiser Permanente, Pﬁzer Inc., Sanoﬁ-Aventis, Shire
Pharmaceuticals and Wyeth-Ayerst ; has served on
advisory boards for Eli Lilly & Company and Wyeth-
Ayerst ; and has had research support for his epi-
demiological studies from Bristol-Myers Squibb,
Eli Lilly & Company, GlaxoSmithKline, Johnson &
Johnson Pharmaceuticals, Ortho-McNeil Pharma-
ceuticals Inc., Pﬁzer Inc. and Sanoﬁ-Aventis.
References
Andlin-Sobocki P, Jonsson B, Wittchen HU, Olesen J
(2005). Cost of disorders of the brain in Europe. European
Journal of Neurology 12 (Suppl. 1), 1–27.
Baker M, Stabile M, Deri C (2001). What do self-reported,
objective, measures of health measure? Journal of Human
Resources 39, 1067–1093.
Breiman L (2001). Random forests. Machine Learning 45, 32.
Breiman L (2009). Statistical modeling : the two cultures.
Statistical Science 16, 199–215.
Breiman L, Friedman JH, Olshen RA, Stone CJ (1984).
Classiﬁcation and Regression Trees. Chapman &
Hall : New York, NY.
Buntin MB, Zaslavsky AM (2004). Too much ado about
two-part models and transformation? Comparing methods
of modeling Medicare expenditures. Journal of Health
Economics 23, 525–542.
Center for Disease Control and Prevention (2004). Health,
United States, 2004. National Center for Health Statistics :
Atlanta, GA.
Craig BM, Busschbach JJ, Salomon JA (2009). Modeling
ranking, time trade-oﬀ, and visual analog scale values for
EQ-5D health states : a review and comparison of methods.
Medical Care 47, 634–641.
Donohue JM, Pincus HA (2007). Reducing the societal
burden of depression : a review of economic costs, quality
of care and eﬀects of treatment. Pharmacoeconomics 25, 7–24.
Duan N, Manning WG, Morris CN, Newhouse JP (1984).
Choosing between the sample-selection model and the
multi-part model. Journal of Business and Economic Statistics
2, 289.
Fortin M, Soubhi H, Hudon C, Bayliss EA, van den Akker
M (2007). Multimorbidity’s many challenges. British
Medical Journal 334, 1016–1017.
Friedman JH (1991). Multivariate adaptive regression splines
(with discussion). Annals of Statistics 19, 1.
Gabilondo A, Rojas-Farreras S, Vilagut G, Haro JM,
Fernandez A, Pinto-Meza A, Alonso J (2010).
Epidemiology of major depressive episode in a southern
European country : results from the ESEMeD-Spain project.
Journal of Aﬀective Disorders 120, 76–85.
Gudex C, Dolan P, Kind P, Williams A (1996). Health state
valuations from the general public using the visual
analogue scale. Quality of Life Research 5, 521–531.
Haro JM, Arbabzadeh-Bouchez S, Brugha TS, de
Girolamo G, Guyer ME, Jin R, Lepine JP, Mazzi F,
Reneses B, Vilagut G, Sampson NA, Kessler RC (2006).
Concordance of the Composite International Diagnostic
Interview version 3.0 (CIDI 3.0) with standardized clinical
assessments in the WHO World Mental Health surveys.
International Journal of Methods in Psychiatric Research 15,
167–180.
Heeringa SG, Wells JE, Hubbard F, Mneimneh Z, ChiuWT,
Sampson N, Berglund PA (2008). Sample designs and
sampling procedures. In The WHO World Mental Health
Surveys : Global Perspectives on the Epidemiology of Mental
Disorders (ed. R. C. Kessler and T. B. U¨stu¨n), pp. 14–32.
Cambridge University Press : New York, NY.
Hosmer DW, Lemeshow S (2001). Applied Logistic Regression,
2nd edn. Wiley & Sons : New York, NY.
Insinga RP, Fryback DG (2003). Understanding diﬀerences
between self-ratings and population ratings for health in
the EuroQOL. Quality of Life Research 12, 611–619.
Jacoby A, Baker GA (2008). Quality-of-life trajectories in
epilepsy : a review of the literature. Epilepsy Behavior 12,
557–571.
Jasso G (2006). Factorial survey methods for studying beliefs
and judgments. Sociological Methods and Research 34,
334–423.
Kessler RC, U¨stu¨n TB (2004). The World Mental Health
(WMH) Survey Initiative Version of the World Health
Organization (WHO) Composite International Diagnostic
Interview (CIDI). International Journal of Methods in
Psychiatric Research 13, 93–121.
Kessler RC, U¨stu¨n TB (eds) (2008). The WHO World Mental
Health Surveys : Global Perspectives on the Epidemiology of
Mental Disorders. Cambridge University Press : New York,
NY.
Knight M, Stewart-Brown S, Fletcher L (2001). Estimating
health needs : the impact of a checklist of conditions and
quality of life measurement on health information derived
from community surveys. Journal of Public Health in
Medicine 23, 179–186.
Krabbe PF (2008). Thurstone scaling as a measurement
method to quantify subjective health outcomes. Medical
Care 46, 357–365.
Krabbe PF, Salomon JA, Murray CJ (2007). Quantiﬁcation of
health states with rank-based nonmetric multidimensional
scaling. Medical Decision Making 27, 395–405.
Krabbe PF, Stalmeier PF, Lamers LM, Busschbach JJ (2006).
Testing the interval-level measurement property of multi-
item visual analogue scales. Quality of Life Research 15,
1651–1661.
Kraemer HC, Kazdin AE, Oﬀord DR, Kessler RC,
Jensen PS, Kupfer DJ (1997). Coming to terms
with the terms of risk. Archives of General Psychiatry 54,
337–343.
Lopez AD, Mathers CD (2007). Inequalities in health status :
ﬁndings from the 2001 Global Burden of Disease study.
In The Global Forum Update on Research for Health, vol. 4
(ed. S. Matlin), pp. 163–175. Pro-Brook Publishing Limited :
London.
Macran S, Kind P (2001). ‘Death ’ and the valuation of
health-related quality of life. Medical Care 39, 217–227.
Maddigan SL, Feeny DH, Johnson JA (2005). Health-related
quality of life deﬁcits associated with diabetes and
Health impacts of physical and mental conditions 885
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0033291710001212
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 11 Jul 2017 at 10:11:14, subject to the Cambridge Core terms of use, available at
comorbidities in a Canadian National Population Health
Survey. Quality of Life Research 14, 1311–1320.
Manning SC (1998). Conﬁguring compliance : a professional
ﬁt. Journal of American Health Information Management
Association 69, 36–38.
Manning WG, Mullahy J (2001). Estimating log models :
to transform or not to transform? Journal of Health
Economics 20, 461–494.
Marquie L, Raufaste E, Lauque D, Marine C, Ecoiﬃer M,
Sorum P (2003). Pain rating by patients and physicians :
evidence of systematic pain miscalibration. Pain 102,
289–296.
McCullagh P, Nelder JA (1989). Generalized Linear Models,
2nd edn. Chapman & Hall : London.
Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V,
Ustun B (2007). Depression, chronic diseases, and
decrements in health : results from the World Health
Surveys. Lancet 370, 851–858.
Mullahy J (1998). Much ado about two : reconsidering
retransformation and the two-part model in health
econometrics. Journal of Health Economics 17, 247–281.
Murray CJ, Lopez AD (1996). Evidence-based health
policy – lessons from the Global Burden of Disease Study.
Science 274, 740–743.
Murray CJL, Lopez AD, Mathers CD, Stein C (2001). The
Global Burden of Disease 2000 Project : Aims, Methods and Data
Sources. World Health Organization : Geneva.
Ohayon MM (2002). Epidemiology of insomnia : what we
know and what we still need to learn. Sleep Medicine Review
6, 97–111.
Ormel J, Petukhova M, Chatterji S, Aguilar-Gaxiola S,
Alonso J, Angermeyer MC, Bromet EJ, Burger H,
Demyttenaere K, de Girolamo G, Haro JM, Hwang I,
Karam E, Kawakami N, Lepine JP, Medina-Mora ME,
Posada-Villa J, Sampson N, Scott K, Ustun TB,
Von Korﬀ M, Williams DR, Zhang M, Kessler RC (2008).
Disability and treatment of speciﬁc mental and physical
disorders across the world. British Journal of Psychiatry 192,
368–375.
Parkin D, Devlin N (2006). Is there a case for using visual
analogue scale valuations in cost–utility analysis ? Health
Economics 15, 653–664.
Pennell B-E, Mneimneh Z, Bowers A, Chardoul S, Wells JE,
Viana MC, Dinkelmann K, Gebler N, Florescu S, He Y,
Huang Y, Tomov T, Vilagut G (2008). Implementation
of the World Mental Health Surveys. In The WHO World
Mental Health Surveys : Global Perspectives on the
Epidemiology of Mental Disorders (ed. R. C. Kessler and
T. B. U¨stu¨n), pp. 33–57. Cambridge University Press :
New York, NY.
Roth T, Jaeger S, Jin R, Kalsekar A, Stang PE, Kessler RC
(2006). Sleep problems, comorbid mental disorders, and
role functioning in the National Comorbidity Survey
Replication. Biological Psychiatry 60, 1364–1371.
Saarni SI, Suvisaari J, Sintonen H, Pirkola S, Koskinen S,
Aromaa A, Lonnqvist J (2007). Impact of psychiatric
disorders on health-related quality of life : general
population survey. British Journal of Psychiatry 190, 326–332.
Salomon JA, Murray CJ (2004). A multi-method approach to
measuring health-state valuations. Health Economics 13,
281–290.
Salomon JA, Tandon A, Murray CJ (2004). Comparability
of self rated health : cross sectional multi-country
survey using anchoring vignettes. British Medical Journal
328, 258.
Schmidt L, Room R (1999). Cross-cultural applicability
in international classiﬁcations and research on
alcohol dependence. Journal of Studies on Alcohol 60,
448–462.
Schnadig ID, Fromme EK, Loprinzi CL, Sloan JA, Mori M,
Li H, Beer TM (2008). Patient–physician disagreement
regarding performance status is associated with worse
survivorship in patients with advanced cancer. Cancer 113,
2205–2214.
Schoenborn CA, Adams PF, Schiller JS (2003). Summary
health statistics for the U.S. population : National
Health Interview Survey, 2000. Vital Health and Statistics 10,
1–83.
Singer MA, Hopman WM, MacKenzie TA (1999).
Physical functioning and mental health in patients with
chronic medical conditions. Quality of Life Research 8,
687–691.
Stiggelbout AM, de Vogel-Voogt E (2008). Health state
utilities : a framework for studying the gap between the
imagined and the real. Value Health 11, 76–87.
Tandon A, Murray CJL, Salomon JA, King G (2002).
Statistical Models for Enhancing Cross-Population
Comparability. Global Programme on Evidence for Health
Policy Discussion Paper no. 42. World Health Organization :
Geneva.
Taubman SL, Robins JM, Mittleman MA, Hernan MA
(2009). Intervening on risk factors for coronary heart
disease : an application of the parametric g-formula.
International Journal of Epidemiology 38, 1599–1611.
Verbrugge LM, Lepkowski JM, Imanaka Y (1989).
Comorbidity and its impact on disability. Milbank
Quarterly 67, 450–484.
Wang PS, Simon GE, Kessler RC (2008). Making the
business case for enhanced depression care : the
National Institute of Mental Health-Harvard Work
Outcomes Research and Cost-eﬀectiveness Study.
Journal of Occupational and Environmental Medicine 50,
468–475.
Whiteford H (2000). Unmet need : a challenge for
governments. In Unmet Need in Psychiatry :
Problems, Resources, Responses (ed. G. Andrews and
S. Henderson), pp. 8–10. Cambridge University Press :
Cambridge, UK.
WHO (2004). The Global Burden of Disease : 2004 Update.
World Health Organization : Geneva.
Wolter KM (1985). Introduction to Variance Estimation.
Springer-Verlag : New York, NY.
Young JG, Hernan MA, Picciotto S, Robins JM (2010).
Relation between three classes of structural models for
the eﬀect of a time-varying exposure on survival. Lifetime
Data Analysis 16, 71–84.
886 J. Alonso et al.
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0033291710001212
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 11 Jul 2017 at 10:11:14, subject to the Cambridge Core terms of use, available at
